Metabolic profiles associated with fat loss in Parkinson’s disease, 2025, Higashi et al

Mfairma

Established Member (Voting Rights)
Found this study interesting, with some relevance to the discussion about rehabilitation and deconditioning in the thread on the Putrino/Systrom/Wust preprint, in terms of the risks of making assumptions about poorly understood phenomena.

Study finds that weight loss in Parkinson’s, previously thought due to “muscle loss, poor nutrition, or deeper metabolic changes,” is due to change in metabolic function that cause selective loss of body fat, but not muscle mass, potentially opening new pathways for treatment:

“…This fat loss is a consequence of a deeper metabolic failure. Key metabolites, such as lactic acid and succinic acid were significantly reduced, indicating impaired glycolysis and dysfunction of the TCA cycle—the body’s primary ‘’main engine’’ for adenosine triphosphate production. This failure means that glucose can no longer be efficiently converted into usable energy.

As a result, the body activates an alternative survival mechanism. Markers of ketone bodies, including acetoacetic acid, were elevated, along with metabolites associated with amino acid catabolism, demonstrating activation of an “emergency engine” that relies on fat and protein breakdown to sustain energy production. In other words, when carbohydrate metabolism fails, the body is forced to burn fat to survive.”

“The study suggests a need to rethink nutritional and therapeutic strategies for PD. Interventions that stabilize glycolysis, improve mitochondrial function, or prevent excessive reliance on fat-derived ketone bodies may represent entirely new treatment approaches, distinct from conventional dopamine replacement therapy.”
 
Metabolic profiles associated with fat loss in Parkinson’s disease, 2025, Higashi et al

Metabolic profiles associated with fat loss in Parkinson’s disease

Higashi, Atsuhiro; Mizutani, Yasuaki; Ohdake, Reiko; Maeda, Yasuhiro; Yoshimoto, Junichiro; Shima, Sayuri; Seino, Yusuke; Ueda, Akihiro; Ito, Mizuki; Suzuki, Atsushi; Watanabe, Hirohisa

Abstract
Background
Weight loss is a substantial non-motor feature of Parkinson’s disease (PD) associated with worse clinical outcomes, but the underlying mechanisms remain poorly understood. Thus, we investigated the mechanisms of PD-related weight loss by examining the correlation between body composition and various plasma metabolites.

Methods
We enrolled 91 patients with PD and 47 healthy controls between July 2021 and October 2023. Body composition was evaluated using bioelectrical impedance analysis. Plasma metabolite profiling was conducted via mass spectrometry, including short-chain and medium-chain fatty acids, Krebs cycle intermediates, ketone bodies and phospholipids. Subsequently, alterations in body composition in PD and their association with plasma metabolites were assessed.

Results
Patients with PD had lower body weight (p=0.003), body mass index (BMI; p=0.001) and body fat mass (p<0.001) compared with controls. Metabolomic analyses revealed that, in patients with PD, glycolysis and Krebs cycle markers (lactic acid and succinic acid) were reduced, while ketone bodies (acetoacetic acid and 3-hydroxybutyric acid), amino acid catabolism-related markers (2-hydroxybutyric acid and 2-oxobutyric acid) and acetic acid were elevated.

Notably, in patients with PD, acetoacetic acid and 3-hydroxybutyric acid negatively correlated with BMI. Phosphatidylcholine (40:2) was also elevated in PD and showed higher levels in individuals at more advanced Hoehn and Yahr stages.

Conclusions
PD-related fat loss was accompanied by a pattern of lower glycolytic activity and higher levels of lipid and amino acid metabolism-related metabolites, consistent with a potential shift in energy utilisation. These findings highlight metabolic pathways as potential targets for interventions to mitigate weight loss in PD.

Web | DOI | Journal of Neurology, Neurosurgery & Psychiatry
 
Back
Top Bottom